Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-21-016458
Filing Date
2021-05-07
Accepted
2021-05-07 16:39:13
Documents
63
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q brhc10024029_10q.htm 10-Q 541217
2 EXHIBIT 31.1 brhc10024029_ex31-1.htm EX-31.1 7379
3 EXHIBIT 31.2 brhc10024029_ex31-2.htm EX-31.2 7405
4 EXHIBIT 32.1 brhc10024029_ex32-1.htm EX-32.1 5265
5 EXHIBIT 32.2 brhc10024029_ex32-2.htm EX-32.2 5407
  Complete submission text file 0001140361-21-016458.txt   3786707

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ocup-20210331.xml EX-101.INS 524639
7 XBRL TAXONOMY EXTENSION SCHEMA ocup-20210331.xsd EX-101.SCH 47466
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ocup-20210331_cal.xml EX-101.CAL 34538
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ocup-20210331_def.xml EX-101.DEF 239165
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20210331_lab.xml EX-101.LAB 550215
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20210331_pre.xml EX-101.PRE 354478
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 21903459
SIC: 2834 Pharmaceutical Preparations